BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $56,000 | -28.2% | 861 | -14.3% | 0.04% | +133.3% |
| Q1 2022 | $78,000 | -10.3% | 1,005 | -0.7% | 0.02% | 0.0% |
| Q4 2021 | $87,000 | +11.5% | 1,012 | +4.8% | 0.02% | 0.0% |
| Q3 2021 | $78,000 | +4.0% | 966 | +4.5% | 0.02% | +5.9% |
| Q2 2021 | $75,000 | +2.7% | 924 | +6.9% | 0.02% | -5.6% |
| Q1 2021 | $73,000 | -7.6% | 864 | -12.4% | 0.02% | +20.0% |
| Q4 2020 | $79,000 | +83.7% | 986 | +86.0% | 0.02% | +66.7% |
| Q3 2020 | $43,000 | -6.5% | 530 | 0.0% | 0.01% | -10.0% |
| Q2 2020 | $46,000 | -6.1% | 530 | -11.1% | 0.01% | -23.1% |
| Q1 2020 | $49,000 | -3.9% | 596 | -3.7% | 0.01% | +18.2% |
| Q4 2019 | $51,000 | -61.7% | 619 | -59.1% | 0.01% | -54.2% |
| Q3 2019 | $133,000 | +44.6% | 1,515 | +21.2% | 0.02% | +14.3% |
| Q2 2019 | $92,000 | -27.0% | 1,250 | -19.3% | 0.02% | -12.5% |
| Q1 2019 | $126,000 | +27.3% | 1,548 | +2.9% | 0.02% | +14.3% |
| Q4 2018 | $99,000 | -4.8% | 1,504 | +11.4% | 0.02% | 0.0% |
| Q3 2018 | $104,000 | +13.0% | 1,350 | +8.0% | 0.02% | +5.0% |
| Q2 2018 | $92,000 | +31.4% | 1,250 | +17.2% | 0.02% | +25.0% |
| Q1 2018 | $70,000 | -1.4% | 1,067 | -2.6% | 0.02% | -5.9% |
| Q4 2017 | $71,000 | – | 1,096 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |